• Citer

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

par Awan, Farrukh F.T.;Bron, Dominique ; [et al.]
Référence British journal of haematology, 167, 4, page (466-477)
Publication Publié, 2014-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Auteur:	Awan, Farrukh F.T.; Bron, Dominique; et al.
Informations sur la publication:	British journal of haematology, 167, 4, page (466-477)
Statut de publication:	Publié, 2014-11
Sujet CREF:	Hématologie
Mots-clés:	CD23
	Chronic lymphocytic leukaemia
	Lumiliximab
	Small lymphocytic lymphoma
Note générale:	SCOPUS: ar.j
	SCOPUS: ar.j
	FLWIN
Langue:	Anglais
Identificateurs:	urn:issn:0007-1048
	info:doi/10.1111/bjh.13061
	info:scp/84911405920
	info:pmid/25130401